Pentixapharm Aktie 138581166 / DE000A40AEG0
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
10.11.2025 08:00:03
|
EQS-News: Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025
|
EQS-News: Pentixapharm Holding AG
/ Key word(s): 9 Month figures/Quarterly / Interim Statement
Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results Berlin, Germany, November 10, 2025 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, will publish its financial results for the third quarter and first nine months of 2025 on Wednesday, November 12, 2025. Management will host a conference call and webcast on the same day to discuss the quarterly results and provide a business update.
Conference Call and Webcast Details Date: Wednesday, November 12, 2025 Time: 3 p.m. CET / 9:00 a.m. EST
Registration link to participate in the conference call: https://webcast.meetyoo.de/reg/BXIDSCew5bUU
Live webcast link: https://www.webcast-eqs.com/pentixapharm-202511
Presentation slides will be posted shortly before the start of the webcast at the Investor Relations section of the Pentixapharm website. A replay of the webcast will be available at this website shortly after the event.
About Pentixapharm Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops first-in-class ligand- and antibody-based radiopharmaceuticals designed to transform patient care across oncology and beyond. Its late-stage pipeline is anchored by CXCR4-targeted programs, including a Phase 3-ready diagnostic candidate for primary aldosteronism and pioneering therapeutic programs in a number of hematological and solid cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-escape marker over-expressed in multiple hard-to-treat cancers. Complemented by reliable isotope supply from Eckert & Ziegler, and a robust global clinical network, Pentixapharm is uniquely positioned to deliver innovative radiopharmaceuticals that address high unmet need, improve patient outcomes, and create significant growth opportunities in one of the fastest-growing areas of precision medicine.
Pentixapharm Investor and Media Contact
10.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Strasse 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2226488 |
| End of News | EQS News Service |
|
|
2226488 10.11.2025 CET/CEST
Nachrichten zu Pentixapharm Holding AG Unitary
Analysen zu Pentixapharm Holding AG Unitary
Kommt 2025 der grosse KI-Crash? Tim Schäfer über Nvidia, OpenAI & die Parallelen zu 1929
Könnte der aktuelle KI-Boom an den Börsen in einen Crash münden – ähnlich wie 1929 oder zur Dotcom-Blase? 📉💻
In diesem spannenden Gespräch mit Tim Schäfer sprechen wir über Parallelen zum historischen Börsencrash, die massive Überbewertung vieler Tech- und KI-Aktien wie Nvidia, Palantir oder Microsoft – und was das für Langfristanleger bedeutet. Ist der Hype finanziell überhaupt noch tragbar? Wie positionieren sich Insider und Grossinvestoren wie Warren Buffett oder Peter Thiel?
💬 Welche Risiken birgt der aktuelle KI-Hype?
💬 Was sagen Insiderverkäufe und Bewertungen über die Marktlage?
💬 Wie sollte man sich als Privatanleger jetzt aufstellen?
Ein Interview für alle, die sich fragen: Ist das noch Wachstum oder schon Wahnsinn?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Pentixapharm Holding AG Unitary | 1.40 | 0.14% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI leicht im Plus -- DAX legt zu -- Asiens Börsen am Montag letztlich höher -- Feiertag in JapanDer heimische Aktienmarkt tendiert netwas fester, während das deutsche Börsenbarometer kräftige Zuschläge verbucht. In Fernost waren zum Wochenbeginn überwiegend Gewinne zu erkennen.